Docetaxel and capecitabine for advanced gastric cancer: investigating dose-dependent efficacy in two patient cohorts

Peter Thuss‐Patience(Charité - Universitätsmedizin Berlin), Peter Reichardt(Helios Hospital Berlin-Buch), Ingo Schwaner(Praxis für Hämatologie und Onkologie), Yasemin Doğan(Kayseri Eğitim ve Araştırma Hastanesi), Kirstin Breithaupt(Charité - Universitätsmedizin Berlin), Frank Rothmann(Klinikum Ernst von Bergmann), M Grothoff(Deutsches Herzzentrum der Charité), Albrecht Kretzschmar(Roche (Switzerland)), Dmitry Bichev(Charité - Universitätsmedizin Berlin), I. W. Blau(Praxis für Hämatologie und Onkologie), Christian Grieser(Charité - Universitätsmedizin Berlin)
British Journal of Cancer
July 26, 2011
10.1038/bjc.2011.278
Cited by 23

Related Papers

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
|The Lancet|2019|2.6k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
|The Lancet|2012|1.4k
Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|751
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort
|European Journal of Cancer|2019|724